| Michael B Cohen, MD | |
|
425 Jack Martin Blvd, Brick, NJ 08724-7732 | |
| (732) 840-3376 | |
| Not Available |
| Full Name | Michael B Cohen |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 45 Years |
| Location | 425 Jack Martin Blvd, Brick, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598794588 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 25MA03794700 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ocean Medical Center | Brick, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Parkway Anesthesia Associates Llc | 2567758931 | 126 |
| North American Partners In Anesthesia Of New Jersey Llc | 5890867410 | 226 |
News Archive
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria, a form of chronic hives.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
Sepsis, commonly called blood poisoning, is a common affliction that can affect people of all ages. A series of simple measures tested at a Norwegian hospital can make a difference in successfully treating sepsis.
MarketWatch reports that insurance companies appear to be coming out in the win column. Meanwhile, a new industry report details some of the health law's "hidden" costs.
Conventional biological wisdom holds that living cells interact with their environment through an elaborate network of chemical signals. As a result many therapies for the treatment of cancer and other diseases in which cell behavior goes awry focus on drugs that block or disrupt harmful chemical signals.
› Verified 9 days ago
| Entity Name | Morris Anesthesia Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194728501 PECOS PAC ID: 4284628645 Enrollment ID: O20040409000402 |
News Archive
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria, a form of chronic hives.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
Sepsis, commonly called blood poisoning, is a common affliction that can affect people of all ages. A series of simple measures tested at a Norwegian hospital can make a difference in successfully treating sepsis.
MarketWatch reports that insurance companies appear to be coming out in the win column. Meanwhile, a new industry report details some of the health law's "hidden" costs.
Conventional biological wisdom holds that living cells interact with their environment through an elaborate network of chemical signals. As a result many therapies for the treatment of cancer and other diseases in which cell behavior goes awry focus on drugs that block or disrupt harmful chemical signals.
› Verified 9 days ago
| Entity Name | North American Partners In Anesthesia Of New Jersey Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548433048 PECOS PAC ID: 5890867410 Enrollment ID: O20080626000318 |
News Archive
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria, a form of chronic hives.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
Sepsis, commonly called blood poisoning, is a common affliction that can affect people of all ages. A series of simple measures tested at a Norwegian hospital can make a difference in successfully treating sepsis.
MarketWatch reports that insurance companies appear to be coming out in the win column. Meanwhile, a new industry report details some of the health law's "hidden" costs.
Conventional biological wisdom holds that living cells interact with their environment through an elaborate network of chemical signals. As a result many therapies for the treatment of cancer and other diseases in which cell behavior goes awry focus on drugs that block or disrupt harmful chemical signals.
› Verified 9 days ago
| Entity Name | Parkway Anesthesia Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518319755 PECOS PAC ID: 2567758931 Enrollment ID: O20160912000258 |
News Archive
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria, a form of chronic hives.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
Sepsis, commonly called blood poisoning, is a common affliction that can affect people of all ages. A series of simple measures tested at a Norwegian hospital can make a difference in successfully treating sepsis.
MarketWatch reports that insurance companies appear to be coming out in the win column. Meanwhile, a new industry report details some of the health law's "hidden" costs.
Conventional biological wisdom holds that living cells interact with their environment through an elaborate network of chemical signals. As a result many therapies for the treatment of cancer and other diseases in which cell behavior goes awry focus on drugs that block or disrupt harmful chemical signals.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael B Cohen, MD 255 W Michigan Ave, Po Box 1123, Jackson, MI 49201-2218 Ph: (517) 787-6440 | Michael B Cohen, MD 425 Jack Martin Blvd, Brick, NJ 08724-7732 Ph: (732) 840-3376 |
News Archive
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria, a form of chronic hives.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
Sepsis, commonly called blood poisoning, is a common affliction that can affect people of all ages. A series of simple measures tested at a Norwegian hospital can make a difference in successfully treating sepsis.
MarketWatch reports that insurance companies appear to be coming out in the win column. Meanwhile, a new industry report details some of the health law's "hidden" costs.
Conventional biological wisdom holds that living cells interact with their environment through an elaborate network of chemical signals. As a result many therapies for the treatment of cancer and other diseases in which cell behavior goes awry focus on drugs that block or disrupt harmful chemical signals.
› Verified 9 days ago
Mihika Shah, Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 425 Jack Martin Blvd, Brick, NJ 08724 Phone: 732-840-2200 | |
Ratna Choudhary, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 425 Jack Martin Blvd, Brick, NJ 08724 Phone: 732-840-3376 | |
Justin Ganz, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 425 Jack Martin Blvd, Brick, NJ 08724 Phone: 732-840-2200 | |
Kaitlyn Bender, APN Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 425 Jack Martin Blvd, Brick, NJ 08724 Phone: 732-836-4415 | |
Charles G Schade, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 425 Jack Martin Blvd, Brick, NJ 08724 Phone: 732-840-3376 | |
Yury Rapoport, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 425 Jack Martin Blvd, Brick, NJ 08724 Phone: 732-840-2200 | |
James Martin Higgins, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 425 Jack Martin Blvd, Brick, NJ 08724 Phone: 732-840-3376 |